Biomarkers in routine diagnosis of pleural effusions
Background: Pleural fluid biochemical analysis is the first step in pleural eﬀusion (PE) diagnostics. Our purpose was to analyse the utility of the biomarkers used at our clinic in the routine diagnosis of PE.
Methods: We retrospectively reviewed the PE levels of proteins, lactate dehydrogenase (LDH), alpha amylase (AA), pH and glucose in 433 patients who were treated at the University Clinic Golnik in a one-year period and compared these values with the final identified aetiology of the eﬀusions.
Results: The majority of the eﬀusions were determined to be a consequence of malignancy (n = 154) or infection (n = 108). In 94 cases the aetiology of the eﬀusions was heart failure and in 54 cases other diseases, while 23 eﬀusions remained aetiologically undetermined. Considering Light’s criteria, the vast majority of the eﬀusions were correctly classified as exudates or transudates (97.1 %). Comparing paramalignant and malignant eﬀusions, we detected significantly lower values of pleural fluid LDH (p < 0.0005) and proteins (p < 0.0005), and higher pH (p < 0.0005) values in the paramalignant eﬀusions.
Conclusion: We have found that pleural LDH and proteins are the most helpful biochemical parameters in our routine diagnosis of pleural eﬀusions and helped us to correctly narrow the aetiological spectrum. Furthermore, significantly higher pleural LDH and protein values and a pH below 7.32 additionally facilitated distinguishing between malignant and paramalignant effusions. Parameters such as glucose and AA are useful in selected cases and have a limited role in routine diagnostics.
Ferreiro L, San José E, González-Barcala FJ, Álvarez-Dobaño JM, Golpe A, Gude F, et al. Derrames pleurales eosinofílicos: incidencia, etiología y significado pronóstico. Archivos de Bronconeumología. 2011;47(10):504–9.
McGrath EE, Anderson PB. Diagnosis of Pleural Effusion: A Systematic Approach. American Journal of Critical Care. 2011;20(2):119–28.
BTS- British Thoracic Society. BTS Pleural Disease Guideline 2010. Thorax. 2010;65(supp 2):1–76.
Light RW. Pleural Effusions. Medical Clinics of North America. 2011;95(6):1055–70.
Porcel JM. Pearls and myths in pleural fluid analysis. Respirology. 2010;16(1):44–52.
Porcel JM, Light RW. Diagnostic Approach to Pleural Effusion in Adults. American Family Physician. 2006;73(7):1211–1220.
Ferrer A, Osset J, Alegre J, Suriñach JM, Crespo E, Fernández de Sevilla T, et al. Prospective clinical and microbiological study of pleural effusions. Eur J Clin Microbiol Infect Dis. 1999;18(4):237–41.
Joseph J, Viney S, Beck B, Strange C, Sahn SA, Basran GS. A Prospective Study of Amylase-rich Pleural Effusions With Special Reference to Amylase Isoenzyme Analysis. Chest. 1992;102(5):1455–9.
Sherr HP. Origin of Pleural Fluid Amylase in Esophageal Rupture. Annals of Internal Medicine. 1972;76(6):985.
Good JT, Taryle DA, Maulitz RM, Kaplan RL, Sahn SA. The Diagnostic Value of Pleural Fluid pH. Chest. 1980;78(1):55–9.
Romero S, Martinez A, Hernandez L, Fernandez C, Espasa A, Candela A, et al. Light’s Criteria Revisited: Consistency and Comparison with New Proposed Alternative Criteria for Separating Pleural Transudates from Exudates. Respiration. 2000;67(1):18–23.
Saguil A, Wyrick K, Hallgren J. Diagnostic approach to pleural effusion. Am Fam Physician. 2014 Jul 15;90(2):99–104.
Romero-Candeira S, Hernández L, Romero-Brufao S, Orts D, Fernández C, Martín C. Is it Meaningful to use Biochemical Parameters to Discriminate Between Transudative and Exudative Pleural Effusions? Chest. 2002;122(5):1524–9.
Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax. 2008;63(1):35–41.
Korczynski P, Krenke R, Safianowska A, Gorska K, Abou Chaz BM, Maskey-Warzechowska M, et al. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions. European Journal of Medical Research. 2009;14(Suppl 4):128.
Fiorelli A, Vicidomini G, Di Domenico M, Napolitano F, Messina G, Morgillo F, et al. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. Interactive CardioVascular and Thoracic Surgery. 2010;12(3):420–4.
Alemán C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, et al. Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions. Medicina Clínica. 2009;133(12):449–53.
Duysinx BC, Larock M-P, Nguyen D, Corhay J-L, Bury T, Hustinx R, et al. 18F-FDG PET imaging in assessing exudative pleural effusions. Nuclear Medicine Communications. 2006;27(12):971–6.
Gu P, Huang G, Chen Y, Zhu C, Yuan J, Sheng S. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21–1 in patients with pleural effusion: a systematic review and meta-analysis. Journal of Clinical Laboratory Analysis. 2007;21(6):398–405.
Cakmak M, Durkan A. Analysis of patients with malignant and paramalignant pleural effusion[cited 2017 Mar 19]. Available from: http://www.alliedacademies.org/articles/analysis-of-patients-with-malignant-and- paramalignant-pleural-effusion.pdf
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.